Equillium Inc to Discuss EQUATE Study in aGVHD at EHA Virtual Congress Transcript
Welcome and thank you for joining us this morning for Equillium's presentation of their top-line data from the EQUATE study in first-line acute graft-versus-host disease.
With me this afternoon to discuss data from the EQUATE study are Mr. Bruce Steel, Chief Executive Officer; Dr. Stephen Connelly, Chief Scientific Officer; and Dr. Dolca Thomas, Chief Medical Officer.
Before we begin, I would like to remind you that any statements made during this call that are not historical are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by these statements as a result of various important factors. This includes those discussed in the Risk Factors section in the Company's most recent annual report on Form 10-K as well as other reports filed with the SEC.
I'll remind you that this call is being recorded and a replay of this call will be available on the Company's Web site following the conclusion of the call. And with that, I'm pleased to turn the call
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |